Compare BHRB & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHRB | TBPH |
|---|---|---|
| Founded | 1852 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 962.7M | 1.0B |
| IPO Year | N/A | N/A |
| Metric | BHRB | TBPH |
|---|---|---|
| Price | $68.37 | $19.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $71.67 | $27.80 |
| AVG Volume (30 Days) | 79.5K | ★ 368.8K |
| Earning Date | 01-22-2026 | 02-23-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 173.76 | N/A |
| EPS | ★ 7.72 | 0.58 |
| Revenue | ★ $340,508,000.00 | $80,327,000.00 |
| Revenue This Year | $37.10 | $70.90 |
| Revenue Next Year | $11.36 | N/A |
| P/E Ratio | ★ $8.84 | $33.66 |
| Revenue Growth | ★ 46.12 | 27.12 |
| 52 Week Low | $47.57 | $7.90 |
| 52 Week High | $70.90 | $21.03 |
| Indicator | BHRB | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 50.55 |
| Support Level | $63.33 | $18.45 |
| Resistance Level | $70.90 | $19.71 |
| Average True Range (ATR) | 1.45 | 0.80 |
| MACD | 0.11 | -0.10 |
| Stochastic Oscillator | 46.90 | 51.63 |
Burke & Herbert Financial Services Corp is the bank holding company. Through its subsidiary, it predominantly serves small to medium-sized businesses, their owners and employees, professional corporations, non-profits, and individuals with various banking products and financial services. Some of its products and service offerings include checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential mortgage, acquisition, construction, and development loans, online banking, mobile banking, and wealth and trust services. The company operates in a single segment, namely Community Banking.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).